Skip to content
Subscriber Only

Sanofi’s Toujeo Drug Shows Promise as Lantus Successor

Sanofi’s experimental insulin Toujeo controlled diabetes better than the company’s best-selling Lantus in three tests that suggest the new drug may help buoy sales when the older one loses patent protection.

In an analysis of three trials of Toujeo, also known as U300, patients who used the drug had 31 percent fewer low blood-sugar incidents compared with those on Lantus, Paris-based Sanofi said in a statement. The data were presented at the American Diabetes Association meeting in San Francisco.